Advertisement
UK markets closed
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.81
    -0.55 (-0.66%)
     
  • GOLD FUTURES

    2,326.90
    -15.20 (-0.65%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,435.82
    -1,746.87 (-3.28%)
     
  • CMC Crypto 200

    1,384.78
    -39.32 (-2.76%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Sage’s Brexanolone IV: FDA Grants Priority Review

Sage’s Brexanolone IV: FDA Grants Priority Review

Sage Therapeutics (SAGE) is a US-based clinical-stage biopharmaceutical company. On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV. The FDA granted a priority review for the drug. Following the news, the stock price increased ~1.8% to the closing price of $154.54 on May 30.